Docmorris With Accelerated And Significant Erx Growth In New Customers, Market Share And Revenue


(MENAFN- EQS Group)

DocMorris AG / Key word(s): Quarterly / Interim Statement
DocMorris with accelerated and significant eRx growth in new customers, market share and revenue
11.07.2024 / 06:58 CET/CEST

Frauenfeld, 11 July 2024

Press release

DocMorris with accelerated and significant eRx growth in new customers, market share and revenue

  • Tripling of new Rx customers since the introduction of CardLink
  • Doubling and continuous increase in eRx market share since January 2024
  • 17 per cent revenue growth of prescription medicines (Rx) compared to the previous quarter

Since mid-April, the“CardLink” redemption channel has been available throughout Germany via the DocMorris app. This new service enables users to redeem e-prescriptions fully digitally. The introduction of CardLink marked a turning point in the acquisition of new customers. The weekly number of new Rx customers has tripled since the CardLink launch. The market share of the e-prescription business is increasing continuously and has doubled in the first six months of 2024.[1] The promise to deliver eRx orders on the next working day is being kept, even with increasing volumes, reaching almost 100 per cent.

DocMorris external revenue[2] grew by 6.4 per cent in local currency in the second quarter of 2024 compared to the same period of the previous year. In Group currency, it rose by 5.9 per cent to CHF 267.7 million. As at the end of June 2024, the number of active customers[3] increased by 300,000 to 10.0 million compared to the previous quarter.

In Germany, external revenue in the second quarter of 2024 rose by 6.7 per cent in local currency compared to the same period of the previous year. The hereafter relevant revenue from e-prescriptions increased by over 50 per cent compared to the previous quarter. The decline in the proportion of revenues from paper prescriptions via statutory health insurers (GKV) from previously over 90 per cent to just under 20 per cent, still had a negative effect in the second quarter. Overall, this led to a significant increase in Rx revenue in local currency of 17 per cent (20 per cent in Group currency) compared to the previous quarter and year-on-year still led to a slight decline of 3.7 per cent. Sales of over-the-counter (OTC) medicines increased by 7.9 per cent in local currency in the second quarter compared to the prior year period.

In Spain and France, an inflection point was achieved in the second quarter with a return to revenue growth of 3.2 per cent in local currency.

The indicative revenue and EBITDA outlook from 20 March 2024 remains in place. As announced previously, a specified outlook will be published with the release of half-year results on 20 August.


Revenue, in CHF million (unaudited, preliminary) 1.4.-30.6.2024 1.4.-30.6.2023 Change




Continuing operations (excl. Swiss business)


DocMorris external revenue 267.7 252.7 5.9%
DocMorris external revenue in local currency 269 253 6.4%
DocMorris 250.5 235.5 6.4%
DocMorris in local currency 252 236 6.9%




Markets


Germany external revenue 250.6 236.1 6.2%
Germany external revenue in local currency 257.3 241.2 6.7%
Germany external revenue Rx 42.6 44.5 -4.4%
Germany external revenue Rx in local currency

-3.7%
Germany external revenue OTC 204.0 189.9 7.4%
Germany external revenue OTC in local currency

7.9%
Germany 233.4 218.9 6.6%
Germany in local currency 239.7 223.6 7.2%
Europe 17.0 16.6 2.5%
Europe in local currency 17 17 3.2%


Revenue, in CHF million (unaudited, preliminary) 1.1.-30.6.2024 1.1.-30.6.2023 Change




Continuing operations (excl. Swiss business)


DocMorris external revenue 530.0 501.4 5.7%
DocMorris external revenue in local currency 543 501 8.4%
DocMorris 496.4 463.0 7.2%
DocMorris in local currency 509 463 9.9%




Markets


Germany external revenue 497.7 468.5 6.2%
Germany external revenue in local currency 518 475 8.9%
Germany external revenue Rx 78.1 89.5 -12.8%
Germany external revenue Rx in local currency

-10.6%
Germany external revenue OTC 412.1 375.7 9.7%
Germany external revenue OTC in local currency

12.5%
Germany 464.0 430.0 7.9%
Germany in local currency 483 436 10.6%
Europe 32.4 32.9 -1.7%
Europe in local currency 33 33 0.7%


The financial figures communicated in this press release are preliminary. The detailed half-year report will be published on 20 August.


Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ..., phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: ..., phone: +49 171 864 888 1


Agenda

20 August 2024 2024 Half-year results (conference call/webcast)
15 October 2024 Q3/2024 Trading update
21 January 2025 Sales 2024
13 March 2025 2024 Full-year results and outlook 2025 (conference call/webcast)
17 April 2025 Q1/2025 Trading Update
8 May 2025 Annual General Meeting, Zurich
19 August 2025 2025 Half-year results (conference call/webcast)
16 October 2025 Q3/2025 Trading Update


DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,038 million serving currently 10 million active customers. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit docmorris.


[1]
DocMorris share of redeemed e-prescriptions compared to the total number of redeemed e-prescriptions according to Gematik in June.

[2]
External revenue consists of the consolidated revenue of DocMorris plus online revenues of pharmacies supplied by DocMorris, less the consolidated revenue from supplying them.

[3]
Customers supplied by DocMorris, either directly or through its partners.


End of Media Release

Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 1943693


End of News EQS News Service

MENAFN11072024004691010666ID1108430663


EQS Group

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.